N-(5-硝基-1,3-噻唑-2-基)戊酰胺 | 14538-17-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: N-(5-硝基-1,3-噻唑-2-基)戊酰胺
• 英文名称: N-(5-nitro-1,3-thiazol-2-yl)pentanamide
• 英文别名: N-(5-nitro-thiazol-2-yl)-valeramide；N-(5-Nitro-thiazol-2-yl)-valeramid
• CAS: 14538-17-1
• 化学式: C₈H₁₁N₃O₃S
• mdl: MFCD04066785
• 分子量: 229.26
• InChiKey: HAQCGFVINUGJBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  116
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(5-硝基-1,3-噻唑-2-基)戊酰胺 、 ZINC03819044 、 1-benzyl-3-(5-nitrothiazol-2-yl)urea 、 、 3-(4-methoxyphenyl)-N-(5-nitro-1,3-thiazol-2-yl)propanamide 、 4-(4-methoxyphenyl)-N-(5-nitro-1,3-thiazol-2-yl)butanamide 、 2-(3-methoxyphenyl)-N-(5’-nitrothiazol-2-yl)acetamide 、 2-(4-Fluorophenyl)-N-(5-nitro-1,3-thiazol-2-yl) propanamide 、 2-(3-methylphenyl)-N-(5-nitro-1,3-thiazol-2-yl)acetamide 、 1-benzyl-3-(naphthalen-1-yl)urea 、 生成 N-butyl-N'-(5-nitro-thiazol-2-yl)-urea
  参考文献：
  名称：

  METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS

  摘要：

  本文描述了促进运动神经元存活以及治疗和诊断神经退行性疾病，如肌萎缩侧索硬化症（ALS）和脊髓性肌萎缩症（SMA）的方法、组合物和试剂盒。

  公开号：

  US20160082015A1
• 作为产物：
  描述：

  戊酸噻唑-2-基酰胺 在 硝酸铵 、 硫酸 作用下， 生成 N-(5-硝基-1,3-噻唑-2-基)戊酰胺
  参考文献：
  名称：

  Synthesis of nitazole and its analogs

  摘要：

  DOI：

  10.1007/bf00765138

文献信息

• [EN] NEW 2-SUBSTITUTED -1,3-THIAZOLE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES DE -1,3-THIAZOLE SUBSTITUE EN POSITION 2
  申请人：ASTRAZENECA AB

  公开号：WO2003089419A1

  公开（公告）日：2003-10-30

  The present invention relates to new compounds of formula I, Wherein Y is NR4CONR4, NR4CO, or NR4; R1 is nitro or COR5; R2 is hydrogen or NH2; R3 is C1-6alkyl or C0-6alkylaryl wherein C0-6alkylaryl may be substituted by A; R4 is hydrogen; R5 is C1-6alkyl; A is independently selected from halo, OR6 and C1-6alkyl; R6 is C1-6alkyl; provided that the compound is not N-(4-Methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea as a free base or a salt thereof as well as a process for their preparation, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.

  本发明涉及公式I的新化合物，其中Y为NR4CONR4、NR4CO或NR4；R1为硝基或COR5；R2为氢或NH2；R3为C1-6烷基或C0-6烷基芳基，其中C0-6烷基芳基可以被A取代；R4为氢；R5为C1-6烷基；A独立地选自卤素、OR6和C1-6烷基；R6为C1-6烷基；前提是该化合物不是N-(4-甲氧基苯甲基)-N'-(5-硝基-1,3-噻唑-2-基)脲的自由碱或其盐，以及其制备方法、含有所述治疗活性化合物的药物配方以及所述活性化合物在治疗中的使用。
• 2-substituted-1,3-thiazole compounds
  申请人：Berg Stefan

  公开号：US20050119321A1

  公开（公告）日：2005-06-02

  The present invention relates to new compounds of formula I, Wherein Y is NR 4 CONR 4 , NR 4 CO, or NR 4 ; R 1 is nitro or COR 5 ; R 2 is hydrogen or NH 2 ; R 3 is C 1-6 alkyl or C 0-6 alkylaryl wherein C 0-6 alkylaryl may be substituted by A; R 4 is hydrogen; R 5 is C 1-6 alkyl; A is independently selected from halo, OR 6 and C 1-6 alkyl; R 6 is C 1-6 alkyl; provided that the compound is not N-(4-Methoxybenzyl)-N′-(5-nitro-1,3-thiazol-2-yl)urea as a free base or a salt thereof as well as a process for their preparation, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.

  本发明涉及公式I的新化合物，其中Y为NR4CONR4、NR4CO或NR4；R1为硝基或COR5；R2为氢或NH2；R3为C1-6烷基或C0-6烷基芳基，其中C0-6烷基芳基可以被A取代；R4为氢；R5为C1-6烷基；A是独立选择的卤素、OR6和C1-6烷基；R6为C1-6烷基；所述化合物不是N-(4-甲氧基苯基)-N'-(5-硝基-1,3-噻唑-2-基)脲的游离基或其盐，以及制备它们的过程、含有所述治疗活性化合物的制药组合物和所述活性化合物在治疗中的应用。
• New 2-substituted - 1,3-thiazole compounds
  申请人：Berg Stefan

  公开号：US20060194854A1

  公开（公告）日：2006-08-31

  The present invention relates to new compounds of formula I, Wherein Y is NR 4 CONR 4 , NR 4 CO, or NR 4 ; R 1 is nitro or COR 5 ; R 2 is hydrogen or NH 2 ; R 3 is C 1-6 alkyl or C 0-6 akylaryl wherein C 0-6 alkylaryl may be substituted by A; R 4 is hydrogen; R 5 is C 1-6 alkyl; A is independently selected from halo, OR 6 and C 1-6 alkyl; R 6 is C 1-6 alkyl; provided that the compound is not N-(4-Methoxybenzyl)-N′-(5-nitro-1,3-thiazol-2-yl)urea as a free base or a salt thereof as well as a process for their preparation, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.

  本发明涉及化合物I的新化合物，其中Y为NR4CONR4，NR4CO或NR4; R1为硝基或COR5; R2为氢或NH2; R3为C1-6烷基或C0-6烷基芳基，其中C0-6烷基芳基可以被A取代; R4为氢; R5为C1-6烷基; A独立选择自卤，OR6和C1-6烷基; R6为C1-6烷基; 前提是该化合物不是游离基或盐形式的N-(4-甲氧基苯甲基)-N'-(5-硝基-1,3-噻唑-2-基)脲，以及制备它们的过程，含有该治疗活性化合物的制药配方以及在治疗中使用该活性化合物。
• 2-Acylamino-5-nitro-1,3-thiazoles: Preparation and in vitro bioevaluation against four neglected protozoan parasites
  作者：Carlos Nava-Zuazo、Fabiola Chávez-Silva、Rosa Moo-Puc、Manuel Jesús Chan-Bacab、Benjamín Otto Ortega-Morales、Hermenegilda Moreno-Díaz、Daniel Díaz-Coutiño、Emanuel Hernández-Núñez、Gabriel Navarrete-Vázquez

  DOI：10.1016/j.bmc.2014.01.029

  日期：2014.3

  The 2-acylamino-5-nitro-1,3-thiazole derivatives (1-14) were prepared using a one step reaction. All compounds were tested in vitro against four neglected protozoan parasites (Giardia intestinalis, Trichomonas vaginalis, Leishmania amazonensis and Trypanosoma cruzi). Acetamide (9), valeroylamide (10), benzamide (12), methylcarbamate (13) and ethyloxamate (14) derivatives were the most active compounds against G. intestinalis and T. vaginalis, showing nanomolar inhibition. Compound 13 (IC50 = 10 nM), was 536-times more active than metronidazole, and 121-fold more effective than nitazoxanide against G. intestinalis. Compound 14 was 29-times more active than metronidazole and 6.5-fold more potent than nitazoxanide against T. vaginalis. Ureic derivatives 2, 3 and 5 showed moderate activity against L. amazonensis. None of them were active against T. cruzi. Ligand efficiency indexes analysis revealed higher intrinsic quality of the most active 2-acylamino derivatives than nitazoxanide and metronidazole. In silico toxicity profile was also computed for the most active compounds. A very low in vitro mammalian cytotoxicity was obtained for 13 and 14, showing selectivity indexes (SI) of 246,300 and 141,500, respectively. Nitazoxanide showed an excellent leishmanicidal and trypanocidal effect, repurposing this drug as potential new antikinetoplastid parasite compound (C) 2014 Elsevier Ltd. All rights reserved.
• KRAVCHENYA, N. A., XIM.-FARMATS. ZH., 1983, 17, N 11, 1340-1342
  作者：KRAVCHENYA, N. A.

  DOI：——

  日期：——